Miyatake Shin-Ichi, Kawabata Shinji, Hiramatsu Ryo, Kuroiwa Toshihiko, Suzuki Minoru, Ono Koji
Prog Neurol Surg. 2018;32:48-56. doi: 10.1159/000469679. Epub 2018 Jul 10.
Boron neutron capture therapy (BNCT) is a promising modality for biochemically targeted, highly selective radiation treatment of various cancers, including malignant gliomas. Currently available results demonstrate the beneficial effect of such therapy on survival of patients with both recurrent and newly diagnosed glioblastomas. The main drawback of BNCT in cases of previously irradiated neoplasms is high rates of symptomatic pseudoprogression and radiation necrosis. For prevention of these complications, concurrent administration of bevacizumab may be helpful. Further studies are needed to establish the optimal therapeutic protocols and to define the exact role of this management option in multimodality treatment strategies. Recent technological developments of accelerator-based neutron sources may simplify placement of the device for BNCT within clinical facilities and lead to wider application of this technique in cases of various cancers.
硼中子俘获疗法（BNCT）是一种很有前景的治疗方式，可对包括恶性胶质瘤在内的各种癌症进行生物化学靶向、高选择性的放射治疗。目前可得的结果表明，这种疗法对复发性和新诊断的胶质母细胞瘤患者的生存具有有益效果。在先前接受过放疗的肿瘤病例中，BNCT的主要缺点是有症状的假性进展和放射性坏死发生率较高。为预防这些并发症，同时给予贝伐单抗可能会有帮助。需要进一步研究以确立最佳治疗方案，并确定这种管理选择在多模态治疗策略中的确切作用。基于加速器的中子源的最新技术发展可能会简化BNCT设备在临床设施中的安置，并导致该技术在各种癌症病例中的更广泛应用。
